Brumm Joshua T's Form 4 filing
Crescent Biopharma, Inc.CBIO · filed Sep 18, 2026
- Accession no.
- 0001628280-26-062701
- Filed
- Sep 18, 2026, 4:02 PM ET
- Trade date
- Sep 16-18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $159.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brumm Joshua TCIK 0001528826 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Referenced by the price of 2 transactions in Table I.
Remarks
Exhibit 24 - Power of Attorney